EP1051405B1 - Novel dihydroxyhexanoic acid derivatives - Google Patents
Novel dihydroxyhexanoic acid derivatives Download PDFInfo
- Publication number
- EP1051405B1 EP1051405B1 EP99900098A EP99900098A EP1051405B1 EP 1051405 B1 EP1051405 B1 EP 1051405B1 EP 99900098 A EP99900098 A EP 99900098A EP 99900098 A EP99900098 A EP 99900098A EP 1051405 B1 EP1051405 B1 EP 1051405B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- amide
- methyl
- dihydroxy
- carboxylic acid
- octyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/52—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to novel dihydroxyhexanoic acid derivatives, methods of use and pharmaceutical compositions containing them.
- the compounds of the invention are potent and selective inhibitors of MIP-1 ⁇ binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes).
- CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes).
- the CCR1 receptor is also sometimes referred to as the CC-CKR1 receptor.
- These compounds also inhibit MIP-1 ⁇ (and the related chemokine shown to interact with CCR1 (e.g.
- autoimmune diseases such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis
- acute and chronic inflammatory conditions such as osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis
- allergic conditions such as asthma and atopic dermatitis
- infection associated with inflammation such as viral inflammation (including influenza and hepatitis) and Guillian-Barre
- transplantation tissue rejection chronic and acute
- organ rejection chronic and acute
- atherosclerosis restenosis
- HIV infectivity co-receptor usage
- granulomatous diseases including s
- MIP-1 ⁇ and RANTES are soluble chemotactic peptides (chemokines) which are produced by inflammatory cells, in particular CD8+ lymphocytes, polymorphonuclear leukocytes (PMNs) and macrophages, J.Biol. Chem. , 2 70 (30) 29671-29675 (1995). These chemokines act by inducing the migration and activation of key inflammatory and immunomodulatory cells. Elevated levels of chemokines have been found in the synovial fluid of rheumatoid arthritis patients, chronic and rejecting tissue transplant patients and in the nasal secretions of allergic rhinitis patients following allergen exposure (Teran , et al ., J.
- PCT publication WO 92/17490 published October 15, 1992, refers to peptides containing at least one O-phosphate monoester or diester. The compounds are claimed to possess activity for inhibiting retroviruses.
- the present invention relates to compounds of the formula I wherein said compound is:
- the present invention also relates to the pharmaceutically acceptable acid addition salts of compounds of the formula I.
- the acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, i.e.
- salts containing pharmacologically acceptable anions such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [ i.e ., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)]salts.
- pharmacologically acceptable anions such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bit
- the invention also relates to base addition salts of formula I.
- the chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of formula I that are acidic in nature are those that form non-toxic base salts with such compounds.
- Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (e.g. , potassium and sodium) and alkaline earth metal cations ( e.g. , calcium and magnesium), ammonium or watersoluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines.
- the present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult respiratory distress syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), transplantation tissue rejection, atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases (including sarcoidosis, leprosy and tuberculosis), in a mammal, preferably a human, compris
- the present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by inhibiting MIP-1 ⁇ binding to the receptor CCR1 in a mammal, preferably a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.
- a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by inhibiting MIP-1 ⁇ binding to the receptor CCR1 in a mammal, preferably a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.
- disorders and conditions are those enumerated in the preceding paragraph.
- the present invention also relates to a method for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult respiratory distress syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), transplantation tissue rejection, atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases (including sarcoidosis, leprosy and tuberculosis) in a mammal, preferably a human, comprising
- the present invention also relates to a method for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or prevention an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.
- the present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult respiratory distress syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), transplantation tissue rejection, atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases (including sarcoidosis, leprosy and tuberculosis) in a mammal, preferably a human, compris
- the present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, preferably a human, comprising a CCR1 receptor antagonizing effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- the present invention also relates to a method for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult respiratory distress syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), transplantation tissue rejection, atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases (including sarcoidosis, leprosy and tuberculosis) in a mammal, preferably a human, comprising
- compositions containing and methods of treating or preventing comprising administering prodrugs of compounds of the formula I.
- Compounds of formula I having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs.
- Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues which are covalently joined through peptide bonds to free amino, hydroxy or carboxylic acid groups of compounds of formula I.
- the amino acid residues include the 20 naturally occurring amino acids commonly designated by three letter symbols and also include, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone.
- Prodrugs also include compounds wherein carbonates, carbamates, amides and alkyl esters which are covalently bonded to the above substituents of formula I through the carbonyl carbon prodrug sidechain.
- Prodrugs also include compounds of formula I in which an amide nitrogen and a hydroxy group when taken together form a cyclic group such as the following formula wherein R 1 and R 2 are as defined in formula I and U and V are independently carbonyl, methylene, SO 2 or SO 3 , and b is an integer from one to three wherein each methylene group is optionally substituted with hydroxy.
- Scheme 1 refers to the preparation of compounds of the formula I having the exact stereochemistry
- compounds of the formula I can be prepared from compounds of formula II by reaction with ammonia or another volatile low molecular weight amine in a polar solvent at a temperature from about -10°C to about 35°C, preferably at about 30°C.
- Suitable solvents include, alcohols, such as methanol, ethanol, or butanols; or ethers such as glyme or dioxane (an acid catalyst may be used with an ether solvent).
- the solvent is methanol.
- Compounds of formula II are prepared by coupling a compound of formula III with an acid of the formula R 1 CO 2 H (or an acid chloride thereof wherein R 1 is quinoxaline-2-carboxylic acid, 7,8 difluoro-quinoline-3-carboxylic-acid or 6,7,8-trifluoroquinoline-3-carboxylic acid).
- Such a coupling reaction is generally conducted at a temperature of about -30°C to about 80°C, preferably about 0°C to about 25°C.
- Suitable coupling reagents which activate the carboxylic acid functionality are dicyclohexylcarbodiimide/hydroxybenzotriazole (DCC/HBT), N-3-dimethylaminopropyl-N'-ethylcarbodiimide (EDC)/HBT, 2-ethyoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ), carbonyl diimidazole (CDI)/dimethylaminopyridine (DMAP), and diethylphosphorylcyanide.
- the coupling is conducted in an inert solvent, preferably an aprotic solvent, such as acetonitirile, dichloromethane, chloroform, and dimethylformamide.
- the preferred solvent is dichloromethane.
- the compounds of formula III can be prepared by deprotection and alkene hydrolysis of compounds of the formula IV by reaction with trifluoro acetic acid.
- Suitable protecting groups, of the formula P include t-butoxycarbonyl.
- Compounds of the formula IV can be prepared by reaction of a compound of formula V with 4-bromo-2-methyl-2-butene, in the presence of a strong base in an aprotic polar solvent.
- Suitable bases include lithium dialkyl amides such as lithium N-isopropyl-N-cyclohexylamide, LDA or potassium hydride.
- Suitable solvents include ethers (such as THF, glyme or dioxane) benzene or toluene, preferably THF.
- the aforesaid reaction is conducted at about -78°C to about 0°C. preferably at about -78°C.
- Un-natural amino acids can be prepared according to the method of Myers et al ., Tet. Lett . 36 , (1995) and Myers et al . J. Am. Chem. Soc ., 117 , 8488-8489 (1995).
- compounds of the formula V can also be made by the method of DeCamp et al ., ( Tetrahedron Lett ., 32 , 1867 (1991)).
- the pressure of each of the above reactions is not critical. Generally, the reactions will be conducted at a pressure of about one to about three atmospheres, preferably at ambient pressure (about one atmosphere).
- the compounds of the formula I which are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent, and subsequently convert the free base to a pharmaceutically acceptable acid addition salt.
- the acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is obtained.
- the acids which are used to prepare the pharmaceutically acceptable acid addition salts of the base compounds of this invention are those which form non-toxic acid addition salts, i.e. , salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [ i.e. , 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts.
- non-toxic acid addition salts i.e. , salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate
- Those compounds of the formula I which are also acidic in nature, are capable of forming base salts with various pharmacologically acceptable cations.
- such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques.
- the chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the herein described acidic compounds of formula I. These non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium, calcium and magnesium, etc.
- salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure.
- they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before.
- stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum product yields.
- the active compounds are potent antagonists of the CCR1 receptors.
- the active compounds are useful in the treatment or prevention of autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult respiratory distress syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), transplantation tissue rejection, atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases (including
- the activity of the compounds of the invention can be assessed according to procedures know to those of ordinary skill in the art. Examples of recognized methods for determining CCR1 induced migration can be found in Coligan, J. E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M., Strober, W. editors: Current Protocols In Immunology , 6.12.1- 6.12.3. (John Wiley and Sons, NY, 1991). One specific example of how to determine the activity of a compound for inhibiting migration is described in detail below.
- the ability of compounds to inhibit the chemotaxis to various chemokines can be evaluated using standard 48 or 96 well Boyden Chambers with a 5 micron polycarbonate filter. All reagents and cells can be prepared in standard RPMI (BioWhitikker Inc.) tissue culture medium supplemented with 1 mg/ml of bovine serum albumin. Briefly, MIP-1 ⁇ (Peprotech, Inc., P.O. Box 275, Rocky Hill NJ) or other test agonists, were placed into the lower chambers of the Boyden chamber. A polycarbonate filter was then applied and the upper chamber fastened. The amount of agonist chosen is that determined to give the maximal amount of chemotaxis in this system (e.g., 1 nM for MIP-1 ⁇ should be adequate).
- THP-1 cells ATCC TIB-202
- primary human monocytes or primary lymphocytes
- Compound dilutions can be prepared using standard serological techniques and are mixed with cells prior to adding to the chamber.
- the chamber is removed, the cells in the upper chamber aspirated, the upper part of the filter wiped and the number of cells migrating can be determined according to the following method.
- the chamber (a 96 well variety manufactured by Neuroprobe) can be centrifuged to push cells off the lower chamber and the number of cells can be quantitated against a standard curve by a color change of the dye fluorocein diacetate.
- the filter For primary human monocytes, or lymphocytes, the filter can be stained with Dif Quik® dye (American Scientific Products) and the number of cells migrating can be determined microscopically.
- Dif Quik® dye American Scientific Products
- the number of cells migrating in the presence of the compound are divided by the number of cells migrating in control wells (without the compound).
- the quotant is the % inhibition for the compound which can then be plotted using standard graphics techniques against the concentration of compound used.
- the 50% inhibition point is then determined using a line fit analysis for all concentrations tested.
- the line fit for all data points must have an coefficient of correlation (R squared) of > 90% to be considered a valid assay.
- compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers.
- the active compounds of the invention may be formulated for oral, buccal, intranasal, parenteral (e.g. , intravenous, intramuscular or subcutaneous) or rectal administration or in a form suitable for administration by inhalation or insufflation.
- the active compounds of the invention may also be formulated for sustained delivery.
- the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. , pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers ( e.g. , lactose, microcrystalline cellulose or calcium phosphate); lubricants ( e.g. , magnesium stearate, talc or silica); disintegrants ( e.g. , potato starch or sodium starch glycolate); or wetting agents (e.g. , sodium lauryl sulphate).
- binding agents e.g. , pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
- fillers e.g. , lactose, microcrystalline cellulose or calcium phosphate
- lubricants e.g. , magnesium stearate, talc or silica
- disintegrants
- Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. , sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g. , lecithin or acacia); non-aqueous vehicles (e.g. , almond oil, oily esters or ethyl alcohol); and preservatives ( e.g. , methyl or propyl p-hydroxybenzoates or sorbic acid).
- suspending agents e.g. , sorbitol syrup, methyl cellulose or hydrogenated edible fats
- emulsifying agents e.g. , lecithin or acacia
- non-aqueous vehicles e.g. , almond oil, oily esters or
- the composition may take the form of tablets or lozenges formulated in conventional manner.
- the active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion.
- Formulations for injection may be presented in unit dosage form, e.g. , in ampules or in multi-dose containers, with an added preservative.
- the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents.
- the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g. , sterile pyrogen-free water, before use.
- the active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. , containing conventional suppository bases such as cocoa butter or other glycerides.
- the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g. , dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g. , dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- the pressurized container or nebulizer may contain a solution or suspension of the active compound.
- Capsules and cartridges for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
- a proposed dose of the active compounds of the invention for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above is 0.1 to 1000 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.
- Aerosol formulations for treatment of the conditions referred to above are preferably arranged so that each metered dose or "puff' of aerosol contains 20 ⁇ g to 1000 ⁇ g of the compound of the invention.
- the overall daily dose with an aerosol will be within the range 0.1 mg to 1000 mg.
- Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1, 2 or 3 doses each time.
- the active agents can be formulated for sustained delivery according to methods well known to those of ordinary skill in the art. Examples of such formulations can be found in United States Patents 3,538,214, 4,060,598, 4,173,626, 3,119,742, and 3,492,397.
- the compounds of the invention can also be utilized in combination therapy with other therapeutic agents such as with immunosuppressant agents such as cyclosporin A and FK-506, Cellcept®, rapamycin, leuflonamide or with classical anti-inflammatory agents (e.g. cyclooxygenase/lipoxegenase inhibitors) such as tenidap, aspirin, acetaminophen, naproxen and piroxicam, steroids including prednisone, azathioprine and biological agents such as OKT-3, anti IL-2 monoclonal antibodies (such as TAC),.
- immunosuppressant agents such as cyclosporin A and FK-506, Cellcept®, rapamycin, leuflonamide
- classical anti-inflammatory agents e.g. cyclooxygenase/lipoxegenase inhibitors
- tenidap tenidap
- aspirin acetaminophen
- the compounds of the present invention possess unexpected solubility that could not be predicted based on United States Patent Application 60/039169, filed February 26, 1997. Specifically, all of the compounds of the present invention have at least 13 fold better solubility than would be expected based on compounds from United States Provisional Application 60/039169.
- quinoxaline-2-carboxylic acid (2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-1(S)-naphthalen-2-ylmethyl-heptyl)-amide (Example 127), and N-1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octy)-5,6-dichloro-nicotinamide (Example 247) both have solubilities of less than 5 ⁇ g/mL when assayed according to the kinetic solubility assay described below.
- LRMS Low Resolution Mass Spectra
- LRMS Low Resolution Mass Spectra
- APCI Atmospheric Pressure Chemical Ionization
- Room or ambient temperature refers to 20-25°C. All non-aqueous reactions were run under a nitrogen atmosphere for convenience and to maximize yields. Concentration at reduced pressure means that a rotary evaporator was used.
- the names for the compounds of the invention were created by the Autonom 2.0 PC-batch version from Beilstein Informationssysteme GmbH (ISBN 3-89536-976-4).
- Solubility of the compounds was determined by a kinetic solubility assay such as described in Advanced Drug Delivery Review , 23 , 3-25 (1997). One embodiment of the method described in Advanced Drug Delivery Review , 23 , 3-25 (1997) is described below. One of ordinary skilled in the art will appreciate that solubitlity can be determined by many different methods.
- Solubility of the compounds is determined at four fixed concentrations and is expressed as ⁇ g/mL. Solubility or insolubility is measured in phosphate buffer using a turbidometric plate reader by automated micro addition of a compound predissolved in DMSO. Solubilities at 50, 100, 200 and 250 or 100, 200, 400 and 500 micrograms/mL can be determined by predissolving 1 mg of compound in sufficient DMSO to reach an initial concentration of 20 or 40 ⁇ g/ ⁇ L.
- a spectramax 250 UV transparent 96 well microplate is filled with 200 ⁇ L of Stock pH 7 phosphate buffer solution.
- a series of 25 absorption readings in a 5 by 5 matrix at a wavelength of 492nm are taken for each well in the microplate containing pH buffer alone. This scan is to be used as a "blank", and the raw optical dispersion (OD) values are used as a baseline.
- DMSO solution Compounds in DMSO solution are then added (column wise) down the microplate. Up to twenty four samples are assayed with each compound being placed in four contiguous wells column wise. Each column of the microplate contains four concentrations of compound in ascending concentration and ascending row order (A-D), or row (E-H). The volume of DMSO stock added to each well ranges from 0.25 to 1.25% of the buffer well volume. The plate is then shaken for 20 minutes to allow for mixing.
- a second scan consisting of a series of 25 absorption readings in a 5 by 5 matrix are taken for each well in the microplate at the same wavelength as the first blank scan.
- the raw compound OD values for each reading in the 5 by 5 matrix are subtracted from the corresponding "blank" values in the 5 by 5 matrix to provide the raw solubility OD data.
- Tecan SLT Spectra Image Reader Data obtained from the Tecan SLT Spectra Image Reader is then analyzed using a Visual Basic computer program (or can be calculated manually according to methods well known to those of ordinary skill in the art), so as to provide solubility data for each compound.
- the compound is considered to be out of solution when the absorbance value is greater than three times the baseline value. All of the compounds of the invention had solubilities greater than 100 ⁇ g/mL.
- Table 1 refers to the preparation of compounds of the formula I by methods analogous to the methods of Preparation 1 and Example 1. TABLE 1 Example. IUPAC Name Melting Point LRMS Solubility 2 Quinoxaline-2-carboxylic acid [4(R)-carbamoyl-1(S)-(3-chloro-benzyl)-2(S),7-dihydroxy-7-methyl-octyl]-amide 161-163 499, 481, 464 >100 ⁇ g/ml 3 7,8-Difluoro-quinoline-3-carboxylic acid (1(S)-benzyl-4(R)-carbamoyl-2(S),7-dihydroxy-7-methyl-octyl)-amide 171-173 501, 484 >250 ⁇ g/ml 4 Quinoxaline-2-carboxylic acid [4(R)-carbamoyl-1(S)-(3-fluoro-benzyl)-2(S),7-dihydroxy-7-methyl-o
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7380198P | 1998-02-05 | 1998-02-05 | |
US73801P | 1998-02-05 | ||
PCT/IB1999/000067 WO1999040061A2 (en) | 1998-02-05 | 1999-01-18 | Novel dihydroxyhexanoic acid derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1051405A2 EP1051405A2 (en) | 2000-11-15 |
EP1051405B1 true EP1051405B1 (en) | 2006-08-23 |
Family
ID=22115885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99900098A Expired - Lifetime EP1051405B1 (en) | 1998-02-05 | 1999-01-18 | Novel dihydroxyhexanoic acid derivatives |
Country Status (37)
Country | Link |
---|---|
EP (1) | EP1051405B1 (pt) |
JP (1) | JP3693916B2 (pt) |
KR (1) | KR100385529B1 (pt) |
CN (1) | CN1177834C (pt) |
AP (1) | AP992A (pt) |
AR (1) | AR016175A1 (pt) |
AT (1) | ATE337307T1 (pt) |
AU (1) | AU752407B2 (pt) |
BG (1) | BG104726A (pt) |
BR (1) | BR9907655A (pt) |
CA (1) | CA2320388C (pt) |
DE (1) | DE69932920T2 (pt) |
DZ (1) | DZ2717A1 (pt) |
EA (1) | EA003137B1 (pt) |
ES (1) | ES2268847T3 (pt) |
GT (1) | GT199900011A (pt) |
HK (1) | HK1034969A1 (pt) |
HR (1) | HRP20000529B1 (pt) |
HU (1) | HUP0100832A3 (pt) |
IL (1) | IL137330A0 (pt) |
IS (1) | IS5562A (pt) |
MA (1) | MA26603A1 (pt) |
MY (1) | MY133125A (pt) |
NO (1) | NO20003965D0 (pt) |
NZ (1) | NZ505724A (pt) |
OA (1) | OA11448A (pt) |
PA (1) | PA8467301A1 (pt) |
PE (1) | PE20000243A1 (pt) |
PL (1) | PL342817A1 (pt) |
SK (1) | SK11262000A3 (pt) |
TN (1) | TNSN99013A1 (pt) |
TR (1) | TR200002248T2 (pt) |
TW (1) | TW470744B (pt) |
UA (1) | UA57824C2 (pt) |
WO (1) | WO1999040061A2 (pt) |
YU (1) | YU47100A (pt) |
ZA (1) | ZA99873B (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000044365A1 (en) * | 1999-01-29 | 2000-08-03 | Millennium Pharmaceuticals, Inc. | Methods for preventing graft rejection and ischemia-reperfusion injury |
PT1204643E (pt) * | 1999-08-20 | 2008-09-15 | Dow Agrosciences Llc | Amidas aromáticas heterocíclicas fungicidas e suas composições, métodos de utilização e preparação |
EP1498417A1 (en) * | 2000-02-04 | 2005-01-19 | Pfizer Products Inc. | Heterocyclic amide derivatives |
EA005320B1 (ru) | 2000-02-04 | 2005-02-24 | Пфайзер Продактс Инк. | Производные гетероциклического амида |
US6740636B2 (en) * | 2000-07-31 | 2004-05-25 | Schering Aktiengesellschaft | Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection |
US6746856B2 (en) | 2000-08-09 | 2004-06-08 | Pfizer Inc. | Microbial conversion of bicyclic heteroaromatic compounds |
EP1269994A3 (en) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
DE60238193D1 (de) | 2001-06-22 | 2010-12-16 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen, enthaltend adsorbate eines arzneimittels in amorpher form |
JP2004534812A (ja) | 2001-06-22 | 2004-11-18 | ファイザー・プロダクツ・インク | 薬物および中性ポリマーの分散物の医薬組成物 |
DE10152351B4 (de) * | 2001-10-18 | 2005-09-22 | Schering Ag | Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat |
JP2005523262A (ja) | 2002-02-01 | 2005-08-04 | ファイザー・プロダクツ・インク | 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物 |
JP2005527604A (ja) * | 2002-05-14 | 2005-09-15 | ファイザー・プロダクツ・インク | ジヒドロフラン2オン誘導体の製造方法 |
WO2003095440A1 (en) * | 2002-05-14 | 2003-11-20 | Pfizer Products Inc. | Dihydroxyhexanoic acid derivatives, their intermediates, and methods of making |
CA2496441C (en) | 2002-08-12 | 2010-03-16 | Pfizer Products Inc. | Pharmaceutical compositions of semi-ordered drugs and polymers |
MXPA05001781A (es) * | 2002-08-12 | 2005-04-25 | Pfizer Prod Inc | Formas cristalinas de [4-carbamoil -1-(3- fluorobencil)-2, 7-dihidroxi- 7-metil- octil]-amida del acido quinoxalina-2- carboxilico. |
US20040097554A1 (en) * | 2002-10-30 | 2004-05-20 | Pfizer Inc | Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents |
US20040087571A1 (en) * | 2002-10-30 | 2004-05-06 | Pfizer Inc | Methods of using CCR1 antagonists as immunomodulatory agents |
BRPI0413277A (pt) | 2003-08-04 | 2006-10-10 | Pfizer Prod Inc | composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4923864A (en) * | 1987-12-15 | 1990-05-08 | Pfizer Inc. | Certain heterocyclic-hexanamides useful for treating hypertension |
PT708085E (pt) * | 1994-10-19 | 2002-11-29 | Novartis Ag | Eteres antivirais de isosteros de substrato de aspartato protease |
DE19708106A1 (de) * | 1997-02-28 | 1998-09-03 | Bosch Gmbh Robert | Einrichtung und Verfahren zur Information über Verkehrsstörungen |
-
1999
- 1999-01-18 TR TR2000/02248T patent/TR200002248T2/xx unknown
- 1999-01-18 KR KR10-2000-7008561A patent/KR100385529B1/ko not_active IP Right Cessation
- 1999-01-18 EP EP99900098A patent/EP1051405B1/en not_active Expired - Lifetime
- 1999-01-18 BR BR9907655-1A patent/BR9907655A/pt not_active Application Discontinuation
- 1999-01-18 AT AT99900098T patent/ATE337307T1/de not_active IP Right Cessation
- 1999-01-18 HU HU0100832A patent/HUP0100832A3/hu unknown
- 1999-01-18 IL IL13733099A patent/IL137330A0/xx unknown
- 1999-01-18 SK SK1126-2000A patent/SK11262000A3/sk unknown
- 1999-01-18 NZ NZ505724A patent/NZ505724A/xx unknown
- 1999-01-18 PL PL99342817A patent/PL342817A1/xx not_active Application Discontinuation
- 1999-01-18 PA PA19998467301A patent/PA8467301A1/es unknown
- 1999-01-18 CN CNB998027138A patent/CN1177834C/zh not_active Expired - Fee Related
- 1999-01-18 AU AU17789/99A patent/AU752407B2/en not_active Ceased
- 1999-01-18 CA CA002320388A patent/CA2320388C/en not_active Expired - Fee Related
- 1999-01-18 JP JP2000530493A patent/JP3693916B2/ja not_active Expired - Lifetime
- 1999-01-18 WO PCT/IB1999/000067 patent/WO1999040061A2/en active IP Right Grant
- 1999-01-18 ES ES99900098T patent/ES2268847T3/es not_active Expired - Lifetime
- 1999-01-18 EA EA200000741A patent/EA003137B1/ru not_active IP Right Cessation
- 1999-01-18 YU YU47100A patent/YU47100A/sh unknown
- 1999-01-18 DE DE69932920T patent/DE69932920T2/de not_active Expired - Lifetime
- 1999-01-18 UA UA2000074534A patent/UA57824C2/uk unknown
- 1999-01-27 GT GT199900011A patent/GT199900011A/es unknown
- 1999-02-01 PE PE1999000071A patent/PE20000243A1/es not_active Application Discontinuation
- 1999-02-01 TW TW088101505A patent/TW470744B/zh not_active IP Right Cessation
- 1999-02-03 MA MA25448A patent/MA26603A1/fr unknown
- 1999-02-03 MY MYPI99000363A patent/MY133125A/en unknown
- 1999-02-03 DZ DZ990018A patent/DZ2717A1/xx active
- 1999-02-03 AR ARP990100443A patent/AR016175A1/es unknown
- 1999-02-03 TN TNTNSN99013A patent/TNSN99013A1/fr unknown
- 1999-02-04 ZA ZA9900873A patent/ZA99873B/xx unknown
- 1999-02-04 AP APAP/P/1999/001457A patent/AP992A/en active
-
2000
- 2000-07-14 IS IS5562A patent/IS5562A/is unknown
- 2000-07-28 OA OA1200000214A patent/OA11448A/en unknown
- 2000-08-04 HR HR20000529 patent/HRP20000529B1/xx not_active IP Right Cessation
- 2000-08-04 NO NO20003965A patent/NO20003965D0/no not_active Application Discontinuation
- 2000-08-29 BG BG104726A patent/BG104726A/xx unknown
-
2001
- 2001-08-15 HK HK01105717A patent/HK1034969A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1051405B1 (en) | Novel dihydroxyhexanoic acid derivatives | |
EP0966443B1 (en) | Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of mip-1-alpha binding to its ccr1 receptor | |
JP2718595B2 (ja) | キノキサリン類およびその製法 | |
US6673801B1 (en) | Dihydroxyhexanoic acid derivatives | |
NZ523610A (en) | A method of treating inflammatory conditions in a non-human mammal comprising administration of dihydroxyhexanoic acid derivatives | |
AU2699701A (en) | Heterocyclic amide derivatives | |
MXPA00007690A (en) | Novel dihydroxyhexanoic acid derivatives | |
US20040087571A1 (en) | Methods of using CCR1 antagonists as immunomodulatory agents | |
CZ20002760A3 (cs) | Nové deriváty dihydroxyhexanové kyseliny a farmaceutický prostředek, který je obsahuje | |
US6858744B2 (en) | Dihydoxyhexanoic acid derivatives, their intermediates, and methods of making | |
US20020198207A1 (en) | Novel Hexanoic acid derivatives | |
US20040049057A1 (en) | Dihydro-furan-2-one derivatives, their intermediates and methods of manufacture | |
CZ9902904A3 (cs) | Deriváty amidů heteroarylhexanových kyselin, farmaceutické kompozice na jejich bázi a způsoby léčení nebo prevence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000726 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 20000726;LT PAYMENT 20000726;LV PAYMENT 20000726;MK PAYMENT 20000726;RO PAYMENT 20000726;SI PAYMENT 20000726 |
|
17Q | First examination report despatched |
Effective date: 20020905 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060823 Ref country code: LI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060823 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20060823 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060823 Ref country code: CH Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060823 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060823 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060823 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 69932920 Country of ref document: DE Date of ref document: 20061005 Kind code of ref document: P |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061123 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061123 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070124 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20060823 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2268847 Country of ref document: ES Kind code of ref document: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20070524 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061124 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070118 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060823 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20100114 Year of fee payment: 12 Ref country code: GB Payment date: 20091211 Year of fee payment: 12 Ref country code: ES Payment date: 20100126 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20100122 Year of fee payment: 12 Ref country code: FR Payment date: 20100125 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20100129 Year of fee payment: 12 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20110118 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20110930 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110118 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 69932920 Country of ref document: DE Effective date: 20110802 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110118 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110118 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20120220 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110802 |